Cysteine proteases from V. cundinamarcensis (C. candamarcensis) inhibit melanoma metastasis and modulate expression of proteins related to proliferation, migration and differentiation

• Autor(a) principal: Fernanda de Oliveira Lemos
• Data de Publicação: 2018
• Outros Autores: Dalton Dittz Júnior, Verlane Gonçalves Santos, Simone da Fonseca Pires, Hélida Monteiro de Andrade, Carlos Edmundo Salas Bravo, Miriam Teresa Paz Lopes
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.3390/ijms19102846; http://hdl.handle.net/1843/56293; https://orcid.org/0000-0002-7070-4412; https://orcid.org/0000-0002-4370-0803; https://orcid.org/0000-0003-2823-4530; https://orcid.org/0000-0001-9980-3169
• topic: Cysteine proteases; Antimetastatic; Melanoma; Cell migration; Melanogenesis; Cell differentiation; Cisteína proteases; Melanoma; Movimento celular; Diferenciação celular

Previous studies showed that P1G10, a proteolytic fraction from Vasconcellea cundinamarcensis latex, reduced the tumor mass in animals bearing melanoma, increased in vitro DNA fragmentation and decreased cell adhesion. Here, we present some molecular and cellular events related to the antimetastatic effect induced by the CMS-2 fraction derived from P1G10 in metastatic melanoma B16-F10 and melanocyte Melan-a. Using difference gel electrophoresis and mass spectrometry, we identified four proteins overexpressed in tumor cells, all of them related to proliferation, survival, migration and cell invasion, that had their expression normalized upon treatment with CMS-2: nucleophosmin 1, heat shock protein 65, calcyclin binding protein and eukaryotic translation initiation factor 4H. In addition, some antioxidant and glycolytic enzymes show increased expression after exposure to CMS-2, along with an induction of melanogenesis (differentiation marker). The down regulation of cofilin 1, a protein involved in cell motility, may explain the inhibition of cell migration and dendritic-like outgrowth in B16-F10 and Melan-a, observed after CMS-2 treatment. Taken together, it is argued that CMS-2 modulates the expression of proteins related to metastatic development, driving the cell to a more differentiated-like state. These effects support the CMS-2 antimetastatic activity and place this fraction in the category of anticancer agent.